Although peripheral blood myelin-autoreactive T cells are thought to play a key role in multiple sclerosis, they are generally considered to have qualitative differences rather than quantitative ones when compared to those found in healthy individuals. Here, we revisited the assessment of myelin-autoreactive T cells in a new approach based on their combined ability to acquire membrane proteins from autologous antigen presenting cells, and to respond to whole myelin extract as the stimulating autoantigen. Using this approach, the myelin-autoreactive T cell frequency in patients with multiple sclerosis was found to be unexpectedly high (n = 22, subtracted values median 2.08%, range 0-6%; background median 1%, range 0-4%) and to exceed that of age/gender-matched healthy individuals significantly (n = 18, subtracted values median 0.1%, range 0-5.3%, P50.0001; background median 1.45%, range 0.1-4%). Higher anti-myelin autoreactivity was stable in patients with multiple sclerosis after several months. These data correlated with whole myelin-induced gamma interferon-enzyme-linked immunosorbent spot assay performed under the same conditions, although the values obtained with enzyme-linked immunosorbent spot assay under all conditions were 58 times lower than with this new method. The myelin-autoreactive T cells were memory T cells expressing CD40L with a CD62 low phenotype, suggesting their ability for homing to tissues. Collectively, these new data show a higher frequency of autoreactive T cells during multiple sclerosis than in age/gender-matched healthy individuals, and support an autoimmune aetiology in multiple sclerosis.
Introduction
Immune system deregulation in multiple sclerosis has long been suggested by the presence of T cells and activated monocytes/ macrophages within lesions of post-mortem brain tissue from patients with multiple sclerosis. The current physio-pathological concept of multiple sclerosis autoimmune aetiology lies in the presence of activated peripheral blood myelin-autoreactive T cells that are able to transmigrate the blood-brain barrier endothelium (for review see Lassmann et al., 2007; Bahbouhi et al., 2009) . To date, however, the peripheral blood myelin-autoreactive T cell frequency has not been consistently shown to differ in patients with multiple sclerosis from that of age-matched healthy individuals (Zhang et al., 1994; Hellings et al., 2001 Hellings et al., , 2002 Tejada-Simon et al., 2001; Bielekova et al., 2004; Berthelot et al., 2008) . An alternative hypothesis involves other abnormalities occurring in multiple sclerosis such as a particular peripheral blood myelin-autoreactive T cell phenotype (Zhang et al., 1994) , a defect in T cell regulation (Viglietta et al., 2004) or a dysfunction of the blood-brain barrier (for review see Markowitz et al., 2007) . Our failure to confirm a defect in circulating CD4 + CD25 + CD127 À T regulatory cells in patients with multiple sclerosis , and to discriminate these patients from healthy individuals in terms of their frequency of myelin-autoreactive CD8 + T cells detected by enzyme-linked immunosorbent spot (ELISPOT) , prompted us to revisit the frequency analysis of peripheral blood myelin-autoreactive T cells using a novel approach. Current peripheral blood myelin-autoreactive T cell frequency estimation is either based on the production of a limited number of cytokines (ELISPOT) or on stimulation by potentially autoimmune peptides or soluble proteins. Precisely assessing peripheral blood myelin-autoreactive T cell frequency in multiple sclerosis with a minimum of measurement bias and by taking into account all possible autoantigens is a prerequisite for establishing multiple sclerosis autoimmune aetiology. In this report, we took advantage of the ability of memory T cells to exchange surface membrane molecules with antigen presenting cells in an antigen-dependent manner by a mechanism called 'trogocytosis' or T cell recognition of antigen presenting cells by protein transfer (TRAP), occurring during dissociation of immune synapses. TRAP was first described in rodents to measure a response against viral antigens or transgenic clones (Beadling and Slifka, 2006; Daubeuf et al., 2006) and was also adapted to humans in the context of cancer or viral diseases (Tomaru et al., 2003; Machlenkin et al., 2008) , although in more favourable experimental contexts than autoimmunity including homogeneous T cell clones (Daubeuf et al., 2006) or T cell detection at the peak of an induced immune response (Beadling and Slifka, 2006; Daubeuf et al., 2009 ). Despite its validation as a reliable method, the TRAP assay has not yet been used to analyse freshly isolated T cells from patients presenting with a possible autoimmune disease, particularly with multiple sclerosis. Current techniques do not measure the global pool of autoreactive T cells because these cells might have different activation patterns and a wide-spectrum of activation thresholds. In this respect, the TRAP assay offers a more global readout. Finally, we used whole brain myelin extract as a source of autoantigens instead of myelin-derived peptides or soluble proteins. We demonstrated that endogenous processing of whole myelin extract and its cross-presentation may enhance peripheral blood myelinautoreactive T cell detection by increasing both the number and types of presented epitopes.
This new experimental approach clearly established a high level of autoreactivity against myelin in blood T cells of patients with multiple sclerosis and showed that these patients presented an unexpectedly high frequency of memory T cell reactivity against myelin determinants. This frequency significantly surpassed that of gender/age-matched normal individuals who only responded weakly to the whole myelin autoantigen. Collectively, our data uphold the concept of an expanded anti-myelin autoreactive T cell pool in multiple sclerosis.
Methods

Patients and healthy individuals
Untreated patients with relapsing-remitting multiple sclerosis (18 females and 4 males, median age 36 years, range 22-60 years) were enrolled in the study. Three patients were seen at the time of their first clinical event (clinically isolated syndrome) but were diagnosed with multiple sclerosis according to the McDonald's criteria. The patients did not receive 'immunomodulatory/immunosuppressant' treatment. The majority of the patients seen at the time of an attack received 1 g/day methylprednisolone (Solu-Medrol Õ ) for 3 days.
However, blood sampling was always done before the beginning of the boluses. The clinical information relative to each enrolled patient with multiple sclerosis is detailed in Table 1 . Multiple sclerosis was diagnosed according to the revised McDonald criteria (Polman et al., 2005) with the Expanded Disability Status Scale (EDSS) scores ranging from 0 to 4.5, and patients were recruited at the Neurology Department of the Nantes University Hospital. Age-and gendermatched healthy individuals (n = 18) were selected for comparison (14 females and 4 males, median age 36 years, range 24-62 years). In addition, the blood samples of five cytomegalovirus (CMV) + and five CMV À patients under haemodialysis were used in preliminary TRAP assays; they were not typed for human leukocyte antigen (HLA) haplotypes. Blood samples from two patients with multiple sclerosis and two healthy individuals with blood CD8 + T cells reacting to major histocompatibility complex (MHC) class I-restricted linear myelin basic protein peptides described in our previous study were also included in the preliminary TRAP assays. The study design was approved by the University Hospital Ethical Committee and all the patients signed an informed consent.
Blood sample processing
Blood samples from each enrolled individual were coded, and peripheral blood mononuclear cells were isolated from fresh blood samples on a Ficoll gradient by gently overlaying 20 ml of 2-fold diluted blood in 1 Â phosphate buffered saline (PBS) on 10 ml Ficoll (Lymphosep TM , Biowest, Nuaille, France) in a 50 ml tube. The tubes were centrifuged at 2500 r.p.m./min for 20 min at 20 C, and the lymphocyte layer at the Ficoll interface collected, washed twice in 1 Â PBS and counted in 0.2% Eosin (viability at least 4 95%). CD45RO + memory lymphocytes and CD14 + monocytes were positively selected with specific microbead-antibody conjugates in accordance with the manufacturer's instructions (Miltenyi Biotech, Paris, France). Briefly, 50-100 Â 10 6 peripheral blood mononuclear cells were first incubated in 400-800 ml staining buffer (0.5% bovine serum albumin and 2 mM EDTA in 1 Â PBS supplemented with 100-200 ml undiluted anti-CD45RO or anti-CD14 microbead-coupled antibodies) (Miltenyi Biotech). The cells were incubated with gentle agitation for 15 min at +4 C, washed and resuspended in 5-10 ml staining buffer. Cells were sorted through manual columns hung on magnets to allow binding of labelled cells and elimination of non-labelled cells. Labelled cells were finally recovered by removing the columns from the magnet and flushing with staining buffer to detach the cells. The purity yield was routinely 495%.
In the preliminary TRAP validation experiment, frozen peripheral blood mononuclear cells of patients with multiple sclerosis previously tested for their myelin autoreactivity were included in the study. Frozen aliquots were thawed by partly melting them in a water bath at 37 C and the cells rapidly transferred to pre-warmed culture medium. The cells were then collected by centrifugation at 1000 r.p.m./min and counted. Roswell Park Memorial Institute culture medium (RPMI) (Sigma-Aldrich, Saint-Quentin Fallavier, France) supplemented with 100 U/ml penicillin, 100 mg/ ml streptomycin, 2 mM L-glutamine and 2% foetal calf serum (Biowest), served as a culture medium throughout the study.
T cell clones
Biotinylated pHLA-A2 monomers, pp65 (495) (496) (497) (498) (499) (500) (501) (502) /A*0201 were synthesized as previously described (Bodinier et al., 2000) by the IFR26 protein core facility (Nantes, France). The HLA-A2 heavy chain carrying an Ala to Val substitution in the 3 domain at position 245 was used to reduce the affinity for CD8 co-receptor. A tetramer was generated after incubation of biotinylated pMHC pp65/ A*0201 monomer with phycoerythrin-conjugated streptavidin. The pp65 (495) (496) (497) (498) (499) (500) (501) (502) /A*0201-reactive sorted T cell clone and Epstein-Barr virus-transformed B-lymphoblastoid cell line (ETB-LCL) were kindly provided by Alexis Morice and Elisabeth Chalmeau (INSERM U892, Nantes, France). The ETB-LCL was typed by HLA class I DNA sequencing.
Antigens
Cytomegalovirus recombinant pp65 protein (Miltenyi Biotech) was used at the dose recommended by the manufacturer. Brain-derived myelin basic protein and proteolipid protein from AbD Serotec (Oxford, UK) were dissolved in RPMI culture medium and used at 30 mg/ml for T cell stimulation. Whole human myelin extract (1 mg lyophilized product) was from AbD Serotec. Myelin was resuspended in RPMI at 0.5 mg/ml, roughly vortexed/sonicated and 10 mg/ml was used for T cell stimulation. Delipidated apolipoprotein A-1 (AbD Serotec) was treated as myelin and served as a control for cell reactivity to lipid-binding protein. Myelin protein-derived linear peptides The table displays all multiple sclerosis patients enrolled in the study at the time of blood collection. *Indicates times in months; **indicates times in days.
were previously described and were all synthesized (Mimotopes, Clayton Australia) and dissolved in 4% dimethyl sulphoxide. All peptides were used at 10 mg/ml for cell stimulation.
Myelin labelling and endocytosis
Whole myelin extract (1 mg) was washed in 1 Â PBS by centrifugation at 2500 r.p.m. for 5 min, then resuspended in N-Hydroxysuccinimido-biotin solution (5 mM in 1 Â PBS) (Perbio Science France SAS, Brebieres, France), vortexed for 20-30 s and incubated for 30 min at 37 C. Excess N-Hydroxysuccinimido-biotin was removed by washing. The biotinylated myelin pellet was then labelled with fluorochrome-streptavidin conjugates (Beckman Coulter, Miami, FL, USA) for 30 min at 37 C. The tubes were centrifuged to recover labelled-myelin pellet, washed in 1 Â PBS by centrifugation (2500 r.p.m. for 1 min repeated three times) to eliminate free fluorochromes and finally resuspended in 1 ml 1 Â PBS. Next, 10 mg/ml of labelled myelin was added to 1 Â 10 5 enriched CD14 + monocytes in 100 ml RPMI overnight in the presence or absence of 10 mM phenylarsine oxide (APO) (Sigma-Aldrich). Non-labelled myelin or cells incubated alone served as negative controls. Myelin-fed monocytes were washed at least three times in 1 Â PBS containing 2 mM EDTA (Sigma-Aldrich) to eliminate free/surface-adsorbed myelin, permeabilized in 1 Â PERMFIX solution (BD Biosciences, Le-Pont-de-Claix, France) and analysed on a flow cytometer (LSRII, BD Biosciences). The background signal was defined by cells incubated alone or with unlabelled myelin. Monocytes phagocyting myelin were characterized by the intracellular presence of the marker initially used to label myelin. In other assays, monocytes were pre-incubated with whole myelin overnight, myelin excess was eliminated by repeated washing steps, and then monocytes were analysed for the expression of HLA-DR.
TRAP assay
The TRAP or trogocytosis protocol was performed as previously described (Beadling and Slifka, 2006; Daubeuf et al., 2006) but with modifications to optimize the direct ex vivo detection and quantification of myelin-autoreactive T cells in human blood samples. Purified CD14 + monocytes (3 Â 10 5 from each patient with multiple sclerosis and healthy individual) were incubated with antigens overnight (for peptides) or 48 h (myelin and soluble proteins) in 2% foetal calf serum-RPMI in 96 round well plates. Meanwhile, the autologous CD45RO + T cells purified on the same day were maintained under resting conditions in culture medium while the monocytes were 'fed' with myelin. Antigen-sensitized monocytes were then washed twice at 2500 r.p.m. for 40 s, biotinylated with 50 ml of 5mM N-Hydroxysuccinimido-biotin for 30 min at 37 C, then washed and labelled with fluorochrome-strepdavidin conjugates for 30 min at 37 C. Labelled monocytes were mixed with 3 Â 10 5 purified CD45RO + lymphocytes in the presence of replenished antigens, centrifuged at 2500 r.p.m. for 40 s to promote cell-cell contacts, and incubated overnight. At the end of the incubation, co-cultures in the plates were centrifuged to discard culture medium, and the cell pellets were resuspended in 2 mM EDTA in 1 Â PBS containing the labelling antibodies (200 ml volumes). The plate contents were then transferred to clean tubes for cytometer reading, vortexed for 20-30 s to disrupt conjugates and antibodies left to bind for 20 min at + 4 C during shaking. The lymphocytes, identified on the basis of their Forward Scatter and Side Scatter properties and by CD3 staining, were then gated and analysed for the acquisition of monocyte-fluorescence expressed as [TRAP (%) = number of fluorescent T cells/total number of gated T cells Â 100]. At least 20 000 events were recorded for each sample tested. For TRAP assay blocking experiments, fluorochrome-labelled monocytes were incubated with 500 ng/ml of mouse polyclonal anti-HLA-II (TU39, BD Biosciences) for 1 h at 37 C or purified mouse immunoglobulin G. The CD45RO + enriched cell fraction was then added and the TRAP assay performed as described above.
In the TRAP experiments using the pp65-tetramer-sorted T cells (responder) and ETB-LCL (antigen presenting cells), ETB-LCL were biotinylated with 1 mM N-Hydroxysuccinimido-biotin for 30 min, washed, labelled with streptavidin-fluorochrome conjugates for 30 min and finally pulsed with 10 mM pp65-derived peptide at 37 C for 1 h. For the TRAP reaction, labelled and pp65-peptide loaded ETB-LCL were mixed with pp65 (495-502) /A*0201 T cells at a ratio of 1 : 4 for 1 h. An anti-CD3 T cell marker, together with pp65-tetramer, were used to identify pp65 (495-502) /A*0201 T cells and to measure TRAP frequency.
Flow cytometry immunostaining
The human antibodies were conjugated to phycoerythrin, fluorescein isothiocyanate, peridinin chlorophyll protein, cy-chrome phycoerythrin or allophycocyanin (antigen presenting cells) including anti-CD4 (clone -43 (G46-6) ] and the unlabelled anti-HLA-II antibody (clone TU39). All these antibodies were purchased from BD Biosciences. Anti-CD40L-phycoerythrin conjugate was from Beckman Coulter.
Proliferation assay
Equivalent numbers of CD45RO + T cells from CMV + and CMV À normal donors (3 Â 10 5 ) were loaded with carboxy-fluorescein succinimidyl ester (5 mM) for 15 min at 37 C, washed three times and co-cultured with 1 Â 10 5 syngeneic CD14 + monocytes (1/3 ratio) in the presence or absence of CMV-pp65 recombinant protein for 3 days. Proliferation in collected co-cultures was defined as the loss rate of the carboxy-fluorescein succinimidyl ester dye in gated CD3 + T cells by comparison to those cultured without the antigen (used to set the background quadrants). Cells were stained for the activation marker CD25 to ensure proliferating cells are activated (by measurement of CD25 bright expression).
ELISPOT assay
ELISPOT assay was performed under TRAP conditions by co-incubation of myelin-sensitized purified monocytes (1 Â 10 5 ) with 3 Â 10 5 CD45RO + lymphocytes in each ELISPOT well plate (Thermo scientific, Rockford, USA), in the presence or absence of whole myelin extract, and incubated overnight (longer incubations resulted in a stronger background signal). As an additional control, CD45RO + lymphocytes were cultured separately in the presence or absence of whole myelin extract. The detection of gamma-interferon (IFN)-producing cell spots was performed in accordance with the manufacturer's instructions. The spots were counted by the ELISPOT reader system (AID, Strassberg, Germany) as previously described . The ELISPOT positive reactivity of the co-cultures against whole myelin extract was defined as a number of spots at least three times the global backgrounds from co-cultures incubated alone and from myelin-stimulated CD45RO + lymphocytes cultured alone. In these assays, whole myelin extract added alone without the cells or CD14 + monocytes cultured alone with whole myelin extract did not form characteristic IFN-spots after stringent washing of the ELISPOT filters. In addition, the ELISPOT assay was also performed by overnight incubation of 5 Â 10 5 total peripheral blood mononuclear cells with or without the same dose of whole myelin extract, followed by spot revelation performed as described above.
Statistical analysis
The two-tailed non-parametric Mann-Whitney test was used for comparison between patients with multiple sclerosis and healthy individuals. Kruskal-Wallis or Friedman tests were used for comparison of more than two groups. Significant differences were set at *P50.05, **P50.01, ***P50.001 (GraphPad Prism 4.0).
Results
TRAP detects antigen-specific T cell response in selected individuals
First, we analysed the TRAP response in individuals with pre-established reactivity against cytomegalovirus or myelin basic protein-derived MHC class I-restricted peptides.
CMV + individuals
Supplementary Fig IFN-spots, range 13-60, P50.008, Supplementary Fig. 2C ) although at a 94-fold lower frequency compared to the TRAP-based estimations. There was, however, a significant correlation between the TRAP and ELISPOT assays ( Supplementary Fig. 2D , r 2 = 0.82, P50.01). Finally, pp65-tetramer sorted T cells stimulated by pp65 peptide-pulsed ETB-LCL (used here as antigen presenting cells) did exhibit a 6.8-fold increase in TRAP signal (68%) compared to stimulation by non-pulsed ETB-LCL (10%) (Supplementary Fig. 3 ).
Individuals with pre-established CD8 + T cells reactive to MHC class I-restricted myelin basic protein peptides
We first looked whether biotinylated and fluorescently labelled myelin (myelin-F*) was internalized in the CD14 + monocytes used for T cell stimulation (Fig. 1A) . As a negative control (designated by no-myelin-F*), non-labelled whole myelin extract was added to CD14 + monocytes in order to suppress the autofluorescence signals that might result either from cells and/or whole myelin extract, or a combination of both. Figure 1A shows that myelin was indeed phagocytosed by monocytes (median 15%, range 20-25%, P50.01) while myelin internalization was nil in the presence of the phagocytosis inhibitor phenylarsine oxide. Finally, the percentage of HLA-DR bright cells was three times higher in myelin-fed monocytes compared to non-fed controls (21 AE 8% for patients with multiple sclerosis and 28 AE 7.8% for healthy individuals versus 7.3 AE 3% and 6.3 AE 4%, respectively; P50.002) (Fig. 1B) . These data suggest monocyte activation by their exposure to whole myelin extract. A possible effect of LPS-contamination of the myelin preparation was unlikely, as suggested by the fact that supernatants harvested from myelin suspension did not induce HLA-DR up-regulation on its own (Fig. 1C) . We previously identified patients with multiple sclerosis and healthy individuals with circulating CD8 + T cells reactive to MHC class I restricted myelin basic protein peptides in the IFN-ELISPOT assay . Frozen peripheral blood mononuclear cells samples from such preselected patients with multiple sclerosis and two healthy individuals were available and were tested for TRAP (n = 4). Irrelevant peptide served to determine the background signal. A representative TRAP reactivity on separated T cells is shown in Fig. 2 T cells (myelin: 1.6% versus control peptide: 0.2%) was observed with whole myelin extract ( Fig. 2A) . CD40L, which is transiently expressed on activated T cells consecutively to their antigenic stimulation (Jaiswal et al., 1996; Blair et al., 2000; McDyer et al., 2002) was also increased on TRAP + CD3 + T cells of the co-cultures stimulated with the myelin basic protein peptide (1.2% CD40L + ) and whole-myelin extract (2.7% CD40L + ), which were 4-and 9-fold higher, respectively, than the corresponding percentage of CD40L in non-stimulated control co-cultures (0.3% CD40L + , Fig. 2B ). Whole myelin extract was thus a stronger CD40L inducer than myelin basic protein-derived peptide. If considering only the TRAP + subpopulation, 60-80% Fig. 3C ). Collectively, these experiments show that monocytes internalized myelin and efficiently cross-presented myelin determinants to CD8 + T cells.
Whole myelin extract induces a strong TRAP signal in a cohort of multiple sclerosis patients with remittingrelapsing disease
Next the frequency of memory CD3 + T cells acquiring monocytederived fluorescence in the presence of the whole myelin extract was analysed in a cohort of 22 untreated patients with multiple sclerosis and 18 gender-and age-matched healthy individuals. The median background signal for patients with multiple sclerosis (median 1%, range 0-4%) and healthy individuals (median 1.45%, range 0.1-4%) was similar (Fig. 4A) . In contrast, median TRAP signal in the presence of the whole myelin extract in patients with multiple sclerosis (median 3.5%, range 1-10%) was increased and highly significantly different from related values in healthy individuals (median 1.45%, range 0.2-7.5%; P50.05). If the background was subtracted from the whole myelin-induced TRAP value in an attempt to measure myelin-specific TRAP signal, patients with multiple sclerosis had 2.08% median (range 0-6%) myelin-autoreactive TRAP + T cells, a value still highly significantly exceeding that of healthy individuals (median 0.1%, range 0-5.3%, P50.0001, Supplementary Fig. 4 ). In addition, a total of six multiple sclerosis patients and five healthy individuals were tested with both whole myelin and apolipoprotein A-1. The median background signal in the absence of antigen measured in these patients with multiple sclerosis (median 1.68%, range 1.25-2.75%) was similar to the signal obtained in the presence of apolipoprotein A-1 (median 1.45%, range 1.35-2.6%), but significantly lower than that measured in the presence of the whole myelin extract (median 3.7%, range 2.85-6.45%, P50.05) (Fig. 4B) . In healthy individuals, the median values of the background (1.65%, range 1.15-2.45%), apolipoprotein A-1 (1.3%, range 1-2.15%) and whole myelin extract (1.60%, range 1.2-4.5%) responses were not different.
Finally, myelin-TRAP reactive T cell frequency was considerably higher than that of IFN producing cells in the ELISPOT with an $58-fold increase. However, there was a significant correlation between ELISPOT and TRAP frequencies in samples tested simultaneously under similar conditions (Fig. 4C, (B) Patients with multiple sclerosis (n = 6) and healthy individuals (n = 5) were tested in the TRAP assay using whole myelin extract and apolipoprotein A-1 or in their absence. In patients with multiple sclerosis, the TRAP signal was significantly higher in the presence of whole myelin extract compared to apolipoprotein A-1 (P50.05, Friedman test). (C) Plotting of %TRAP versus ELISPOT in patients with multiple sclerosis shows a significant correlation (r 2 = 0.86, P50.001, linear regression test). (Di) Patients with multiple sclerosis (n = 7) and healthy individuals (n = 6) were tested for ELISPOT under the same conditions as the TRAP assay (monocytes and CD45RO + cell co-purification) or (Dii) under 'conventional conditions' (un-fractioned peripheral blood mononuclear cells, overnight incubation, patients with multiple sclerosis n = 3 and healthy individuals n = 3). The number of IFN-spots tended to increase in the multiple sclerosis group under TRAP conditions but no statistically significant difference was found between patients with multiple sclerosis and healthy individuals (P = 0.0528). (E) Fresh blood samples of three patients with multiple sclerosis initially tested (M0, multiple sclerosis Patients 15, 17 and 19; Table 1 ) were retested 7 months later by the myelin-TRAP assay (M7). In parallel, three age-matched healthy individuals also initially included in the study were retested. The figure shows the median background or TRAP signals at M0 and M7. (F) TRAP + T cells reacting to the whole myelin extract expressed CD40L at higher levels than TRAP À ones (n = 9, P50.001, Mann-Whitney test). *P50.05; **P50.01; ***P50.001.
Anti-myelin T cell frequency in multiple sclerosis in the absence of whole myelin extract in ELISPOT assays performed under TRAP conditions (co-cultures of myelin-loaded monocytes and syngeneic CD45RO + T cells), the number of total INF spots in patients with multiple sclerosis (median 124.5 INF spots, range 72-265 INF spots) was significantly higher than that in healthy individuals (median 42 INF spots, range 10-129 INF spots, P50.05, Mann-Whitney) (Fig. 4D) . The ELISPOT assay was also performed using 'conventional conditions': total un-fractioned peripheral blood mononuclear cells incubated overnight (Hellings et al., 2001; Van der Aa et al., 2003) or for 48 h with whole myelin extract (Olsson et al., 1990; Sun et al., 1991; Andersson et al., 2002 (Fig. 4D) . Collectively, the data indicate that untreated patients with multiple sclerosis are characterized by a high frequency of myelin autoreactive T cells and substantially differed from healthy individuals on the basis of the number of circulating memory T cells reacting against myelin-prepulsed autologous antigen presenting cells; and this difference was more apparent under TRAP conditions than normal conditions. TRAP signal is stable over time in patients with multiple sclerosis and healthy individuals Table 1 ) initially tested (M0) were retested seven months later (M7) by the myelin-TRAP assay. In parallel, three age-matched healthy individuals also initially included in the study were retested.
In Fig. 4E , the median background signals for patients was 1.8% (range 1.5-3%) and 2.2% (range 2.1-2.9%) at M0 and M7, respectively. On the other hand, the myelin-TRAP signal was 5.65% (range 4.8-7%) and 6.9% (range 6.6-8.3%) at M0 and M7, respectively. Thus, TRAP was roughly stable over time in three patients with multiple sclerosis. A similar observation was made for healthy individuals (median background at M0: 2.95%, range 1.8-3.25% versus M7: 3.6%, range 0.7-3.7% and myelin TRAP-signal at M0: 2.6%, range 1.8-3.9% versus M7: 3.3%, range 1.1-4.9%). At both time points, the myelin-TRAP signal seemed to be higher in patients with multiple sclerosis compared to healthy individuals. Fig. 5A ). In contrast, TRAP + T cells had roughly similar median frequencies of CD95 + (Fig. 5B , median 33%, range 30-39%) and HLA-DR + (Fig. 5C , median 18%, range 14-20%) compared to TRAP À T cells (median 36%, range 36-40% for CD95 and median 18%, range 10-51% for HLA-DR). Finally, whole myelin TRAP reactivity was detected at similar levels in both CD4 + and CD4 À T cells in patients with multiple sclerosis (Fig. 6A , inserted representative dot blot). In these experiments, we used only CD4 and CD3 antibodies. Therefore, if the majority of CD3 + CD4 À T cells correspond to CD8 + T cells, at least a part of them may also correspond to double negative T cells. Fig. 6B shows that whole myelin-induced TRAP + CD3 + CD4 + median value in patients with multiple sclerosis (median 3.8%, range 1.5-5%) was decreased to the background levels in gated CD4 + CD3 + T cells (median 0.65%, range 0.3-2%, P50.01) by the addition of anti-MHC class II blocking antibodies in the test, indicating that the myelin-induced TRAP + signal was T cell receptor dependent. It should be noted that the antibodies could not abolish the background signal, suggesting that some antigen presenting cell molecule transfer occurred in a T cell receptor-independent manner.
Correlations of myelin-specific TRAP values with history of relapses and EDSS scores in patients with multiple sclerosis
Further analysis of the data showed that myelin-specific response was significantly higher in patients tested at the time of a relapse (median 3.2%, range 2.6-4.2%) as compared to healthy individuals (median 0.1%, range 0-5.3%, P50.001, KruskalWallis test). This response in the remaining patients with multiple sclerosis seen during a remission period was also significantly higher (median 1.55%, range 0-6%, P50.01, Kruskal-Wallis test) than in healthy individuals (Fig. 7A ). In addition, if patients with multiple sclerosis are ranked according to EDSS scores, the data suggest that those with the highest EDSS scores also had the highest level of myelin autoreactive T cell frequency (median 3%, range 2.6-6%) compared to those with relatively lower EDSS scores (median 1.6%, range 0-4.24%) or to controls (median 0.1%, range 0-5.3%; P50.0001; Fig. 7B ). Both multiple sclerosis subgroups still had a median frequency of memory autoreactive T cells to myelin significantly higher than healthy individuals. No statistical significance could be found between age-matched female and male patients with multiple sclerosis in terms of myelin-specific TRAP values.
Discussion
The question of whether or not peripheral blood myelinautoreactive T cells are more numerous in peripheral blood of patients with multiple sclerosis compared to healthy individuals is an important issue when understanding the disease process. Most studies have reported similar frequencies of autoreactive T cells in groups of patients with multiple sclerosis and healthy individuals (Zhang et al., 1994; Diaz-Villoslada et al., 1999; Hellings et al., 2001 Hellings et al., , 2002 Tejada-Simon et al., 2001; Van der Aa et al., 2003; Bielekova et al., 2004) including our own on CD8 + T cells . However, some reports have shown higher frequencies in patients with multiple sclerosis (Sun et al., 1991; Chou et al., 1992; Pelfrey et al., 2000) or a higher level of myelin autoreactivity in patients with multiple sclerosis, without a specific estimate of peripheral blood myelin-autoreactive T cell frequencies (Kerlero de Rosbo et al., 1997; Zang et al., 2004) . Two important factors might underline these discrepancies: the type of autoantigens used and the peripheral blood myelin-autoreactive T cell detection method. In fact, none of these studies have used whole myelin extract as the autoantigen but myelin-derived peptides or molecules that probably do not represent all determinants that could be involved in the disease. In addition, the ELISPOT or Limiting Dilution Assay readouts only detect autoreactive T cells secreting a limited number of cytokines (usually INF-) or able to proliferate, but not cells secreting other cytokines or with a high activation threshold. For example, Bieganowska et al. (1997) reported a frequency of blood T cells expressing the myelin basic protein p85-99-associated T cell receptor chain transcripts as high as 1/300, which far exceeded the frequencies they calculated by Limiting Dilution Assay (1 Â 10 À5 -10 À6 ) (Bieganowska et al., 1997) .
In an attempt to improve the estimates of myelin-autoreactive T cell frequency, we adopted two novel approaches including the use of whole myelin extract as the autoantigen and the transfer of plasma membrane proteins from autologous antigen presenting cells to T cells upon immune synapse formation, a cytokine and cell proliferation independent readout which measures T cell engagement in an immune synapse, an obligatory step for a T cell immune response (for review see Reichardt et al., 2007) and allows an estimation of antigen-specific T cell frequency whatever the restricting MHC allele (Tomaru et al., 2003; Beadling and Slifka, 2006; Daubeuf et al., 2006 Daubeuf et al., , 2009 Puaux et al., 2006; Machlenkin et al., 2008) . Utilization of whole myelin extract was suggested by the in vivo observation where monocytes/ macrophages contain myelin determinants in brain tissue during multiple sclerosis (for review see Lassmann et al., 2007) . Boven et al. (2006) showed that myelin-loaded monocytes express several anti-inflammatory markers and possibly down-regulate the immune response in brain tissue.
Because the TRAP assay has been predominantly described in animal models (Beadling and Slifka, 2006; Daubeuf et al., 2006 Daubeuf et al., , 2009 , our study conducted in humans included certain validation steps. We first tested TRAP using CMV-pp65 antigen in individuals with positive CMV serology, and by testing the response to whole myelin extract in individuals in whom the presence of circulating CD8
+ peripheral blood myelin-autoreactive T cells had been pre-established by ELISPOT . About 4% blood memory T cells of CMV + donors were pp65-TRAP reactive whereas no response was observed in CMV À subjects.
These frequencies in subjects with positive serology at a distance from the acute disease are within the range of frequencies reported in human subjects using CMV-specific tetramers (Gillespie et al., 2000) or by flow cytometry intracellular cytokine staining (Sylwester et al., 2005) . In addition, pp65-TRAP reactivity correlated to pp65 antigen ability to induce T cell proliferation (CSFE) or IFN secretion (ELISPOT). However, pp65-TRAP + T cell frequencies were 94-fold higher than those measured by the ELISPOT, suggesting that using IFN as the unique parameter to measure the T cell response can result in a gross underestimation of the frequency of committed cells, as also reported recently in animals where the authors have also found comparable differences in the frequencies estimated by ELISPOT (0.01%) and TRAP assays (4.77%) (Daubeuf et al., 2009) . It is possible that INF-negative TRAP + T cells might express other types of cytokines (interleukin-4, -17) or might have a regulatory function. Importantly, TRAP detected a CD8 response both in the presence of MHC class I restricted peptides and whole myelin extract in the test, indicating cross-presentation to CD8 + T cells. Using this experimental strategy in patients with multiple sclerosis (n = 22) and age/gender-matched healthy individuals (n = 18), we showed that 3.5% (range 1-10%) of T cells in patients with multiple sclerosis acquired labelled plasma membrane proteins from their myelin-pulsed autologous antigen presenting cells, which strongly exceeded the background signal and that observed in the group of healthy individuals. When re-tested seven months after the first analysis, the TRAP signal remained stable over time in three patients with multiple sclerosis and three healthy individuals, but was still higher in the former. This stability might indicate continuous stimulation or survival of myelin-specific memory T cells in patients with multiple sclerosis. The antigen specificity of the TRAP phenomenon has also been suggested by linear correlation with tetramer reactivity, dependence upon MHC loading with the specific antigenic peptide (Tomaru et al., 2003 et al., 2008) and cytotoxic function of isolated TRAP + T cells towards target cells pulsed with specific antigenic peptides (Tomaru et al., 2003; Daubeuf et al., 2006) . Despite these studies suggesting that TRAP is T cell receptor dependent, we found that MHC blocking did not eradicate the background signal, indicating that at least some memory T cells interact with monocytes in a T cell receptor-independent manner. This is also suggested by the relatively high background signal we observed in the CMV-tetramer-sorted T cell line. It is thus unlikely that this background only reflects the physiological size of an endogenous T cell memory pool against environmental antigens and engaging T cell receptor-mediated synapses with antigen presenting cells. Such antigen-independent background signals have also been observed in other TRAP studies (Kondo et al., 2001; Revy et al., 2001; Daubeuf et al., 2006 Daubeuf et al., , 2009 Hudrisier et al., 2007; LeMaoult et al., 2007) . Because the synapses formed in the absence of antigen seem to be functional and induce T cell survival (Kondo et al., 2001; Revy et al., 2001) , they should contribute to the background in both healthy subjects and patients with multiple sclerosis, and thus cannot explain the myelin-induced difference between these groups. For these reasons our data and conclusions were only based on the net increase in TRAP signal observed in the absence and presence of whole myelin extract in the test. Interestingly, this antigen-mediated increase was abolished by blocking MHC class II in CD4 + T cells. In addition, the background levels were identical in patients with multiple sclerosis and healthy individuals who thus only differed after the addition of myelin antigens. TRAP assays were performed with enriched CD45RO + T cells rather than un-fractioned CD14-depleted peripheral blood mononuclear cells to minimize recruitment of CD45RO À naïve T cells in the test. The importance of using total myelin extract as antigen was also suggested by the fact that total myelin extract-induced ELISPOT also discriminated patients with multiple sclerosis from normal individuals. The discriminative capacity of the ELISPOT was significant under TRAP conditions but did not reach significance under 'conventional conditions' (despite showing the same trend), probably because only three patients with multiple sclerosis and three healthy individuals were tested in this setting. Using a 'conventional ELISPOT setting' with 18-20 or 48 h of incubation yielded roughly similar results. CD40L was expressed at higher level on TRAP + T cells. CD40L
has indeed been reported to be involved in immune synapse formation, antigen presenting cell maturation and their ability to prime T cell responses (for review see Howard and Miller, 2004; Schuurhuis et al., 2006) suggesting that the antigen-driven TRAP signal was mediated by cognate interaction of T cells with autologous antigen presenting cells. The higher CD40L expression on TRAP + T cells is in accordance with the study by Frentsch et al. (2005) , which shows that CD40L can be used as a marker to track and quantify antigen-specific T-helper cells. In addition, increased CD62L low cells of TRAP + phenotype suggests that these cells could gain access to the brain by crossing the blood brain barrier. This possibility is also suggested by the significant correlations between TRAP values and more recent relapses or EDSS scores in patients with multiple sclerosis.
Unexpectedly, the expression of other activation markers (CD95 and HLA-DR) did not differ between TRAP À and TRAP + T cells.
We have no clear explanation for this lack of up-regulation and can only speculate that acquisition of foreign antigen presenting cell membranes by T cells might mask some binding sites of the phenotyping antibodies or that activated cell subpopulation could be more promoted towards apoptosis. The median frequency of myelin-driven autoreactivity in memory T cells of patients with multiple sclerosis 2.07% (range 0-4.24%) belongs to another level of magnitude compared to previously estimated frequencies in multiple sclerosis, including Limiting Dilution Assay (0.9-1.2 Â 10 À6 ) or ELISPOT studies
(1-4 Â 10
À5
) (Zhang et al., 1994; Hellings et al., 2001 Hellings et al., , 2002 Van der Aa et al., 2003; Berthelot et al., 2008) . Thus, estimation of autoreactive T cell frequency is highly dependent on methodology and most likely has been underestimated as shown by Tomaru et al. (2003) , when measuring human T-lymphotropic virus type I and cytomegalovirus-specific CD8 + T cells by a modified TRAP assay. Lipids (70% of whole myelin) have been reported possibly to exert a co-stimulatory function (Simon et al., 1995; Knigge et al., 1996) . A lipid-bound native-like preparation of myelin basic protein has been associated with a higher T cell proliferation response in patients with multiple sclerosis than in healthy individuals, compared to purified lipid-free myelin basic protein (Mazzanti et al., 1998) . We tested apolipoprotein A-1 as an irrelevant antigen and we did not find an increased TRAP response in patients with multiple sclerosis or in healthy individuals, suggesting that lipid-binding protein motifs were not sufficient to trigger TRAP. Our data cannot exclude the possibility that patients with multiple sclerosis and healthy individuals differ in their response to lipids. However, the TRAP signal was restricted to gated CD3 + (CD45RO + memory T cells) known to react only with MHC-peptide complexes. The difference in TRAP positivity obtained with apolipoprotein A-1 and whole myelin extract suggests that CD3 + T cells from patients with multiple sclerosis recognized specific myelin antigenic determinants regardless of the lipid-binding motifs. The myelin-TRAP reactive T cell subpopulation likely contains multiple antigen specificities, which also partly explains the high frequency of T cells responding to myelin extract and might be related in part to a molecular mimicry phenomenon as hypothesized in multiple sclerosis (for reviews see Salvetti et al., 2009; Stinissen and Hellings, 2008) . High peripheral blood myelin-autoreactive T cell frequencies in patients with multiple sclerosis could therefore reflect continuous stimulation by environmental antigens expanding the initial anti-myelin memory pool. Finally, and with the caution required to interpret relatively small (but also clinically homogeneous) cohorts of patients, our approach was able to discriminate patients with multiple sclerosis according to the presence of recent relapses and severity of the disease (EDSS score), suggesting that the test could be useful in clinics either as a prognostic or a diagnostic tool.
Collectively, our data show a high frequency of anti-myelin memory CD3 + T cells in the blood of patients with multiple sclerosis with an activated phenotype CD40L + CD62L low . In contrast to most of the previously published studies, this finding suggests an abnormal and strongly enlarged autoreactive memory T cell pool in multiple sclerosis, therefore strongly supporting the autoimmune aetiology of the disease. Nevertheless, this study warrants further confirmation of the difference of T cell frequencies against myelin between patients with multiple sclerosis and healthy individuals using a larger cohort and a blinded experimental setting. The measurement of surface membrane protein exchange in combination with the use of whole myelin extract as the triggering antigen would thus allow substantial progress in the characterization of the autoreactive T cells in multiple sclerosis and possibly other autoimmune diseases.
